GleamWall
中文EN

EVAX Evaxion A/S IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1828253 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY125.1%
TTM net income YoY27.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-122.7%
Net margin-102.4%
FCF margin-88.2%
EBITDA margin—

Returns

ROE-100.2%
ROA-37.7%
ROIC (approx.)—
Asset turnover0.37x

Leverage & solvency

Liabilities / assets40.0%
Debt / equity0.32x
Current ratio5.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302024Q22024-06-302023Q22023-06-302023Q1*2023-03-312022Q22022-06-302022Q12022-03-312021Q4*2021-12-312021Q32021-09-30
Income statement
Revenue$37,000$154,000$0—————
R&D expense$2.17M$2.75M$2.94M—$4.11M$4.80M$6.15M$4.42M
SG&A expense$2.21M$1.98M$2.74M—$2.15M$1.59M$1.57M$1.50M
Operating income-$4.34M-$4.58M-$5.68M—-$6.26M-$6.40M-$7.72M-$5.91M
Interest expense$202,000$185,000$177,000—$225,000$158,000-$838,000$51,000
Pretax income-$5.03M-$6.40M-$5.91M—-$4.95M-$6.04M-$7.05M-$5.67M
Income tax-$195,000-$199,000-$225,000—-$177,000-$247,000$1.32M-$425,000
Net income-$4.83M-$6.20M-$5.68M-$6.24M-$4.77M-$5.79M-$8.37M-$5.25M
EPS (basic)-0.02-0.12-0.21—-0.20-0.25—-0.27
EPS (diluted)——-0.21—-0.20-0.25—-0.27
Balance sheet
Cash & equivalents$14.75M$7.99M$7.12M—$25.25M$31.41M$32.17M$11.94M
Receivables——————$1.14M—
Current assets$18.18M$10.70M$11.37M—$28.53M$35.38M$34.70M$16.32M
PP&E, netmay include right-of-use assets (IFRS)$3.62M$3.90M$4.58M—$4.72M$5.11M$5.17M$5.16M
Intangibles————$85,000$91,000$93,000$95,000
Total assets$22.45M$15.23M$16.75M—$34.00M$41.08M$40.16M$24.12M
Current liabilities$5.32M$3.82M$4.05M—$4.41M$4.69M$4.32M$3.92M
Short-term debt$184,000$158,000$152,000—$119,000$125,000$126,000$159,000
Long-term debt$9.03M$8.26M$8.08M—$7.34M$7.72M$1.04M$1.10M
Total debt$9.21M$8.42M$8.23M—$7.46M$7.84M$1.17M$1.26M
Total liabilities$16.22M$13.98M$14.22M—$13.85M$14.69M$7.73M$7.47M
Shareholders' equity$6.23M$1.25M$2.54M$6.58M$20.15M$2.54M$32.44M$16.65M
Net debt-$5.53M$427,000$1.11M—-$17.80M-$23.57M-$31.00M-$10.69M
Cash flow statement
Operating cash flow————-$5.19M-$8.19M-$4.12M-$6.29M
Capital expenditure————$83,000$181,000$176,000$332,000
Free cash flow————-$5.27M-$8.37M-$4.29M-$6.63M
Investing cash flow————-$77,000-$159,000-$177,000-$331,000
Financing cash flow————-$300,000$7.74M$24.65M-$65,000
Stock-based compensation————$300,000———

Free plan shows the latest 8 periods; Pro shows all 14 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.